CGS – The Cancer Genome Summit
Conference - Boston, MA, United States
The only meeting dedicated to translating the cancer genome into better personalized therapies and improving patient outcomes in the clinic.
Advances in sequencing technology are unlocking the cancer genome and driving the explosion of a new genomic era of cancer drugs and diagnostics. With inexpensive sequencing and analysis encouraging innovation in the field, the next hurdle to overcome lies within translating this into the clinic.
The 2nd Cancer Genome Summit is the worlds only commercially focused meeting dedicated to helping drug and diagnostic developers, academics and clinicians unlock this information rich resource.
Following on from the great success of the first Cancer Genome Summit last year, this meeting will feature unparalleled insights from pioneering experts to discuss how they can overcome challenges associated with bridging the gap between the cancer genome and the development of personalized therapies.
Industry experts will be discussing strategies to better identify driver mutations, how to analyse genomic data effectively, the use of genomic and pharmacological modeling to stratify patients, and how to translate cancer genome information into the clinical setting.
Imagine yourself in a room full with the leading pharma, biotech and academic organizations all speaking about how they are unlocking the cancer genome to revolutionize their drug development programs.
(Courtesy of hansonwade.com)
CGS – The Cancer Genome Summit
Tue, Dec 04, 2012 - Thu, Dec 06, 2012
Revere Hotel Boston Common
200 Stuart Street, Boston MA, 02116, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.